Organisation paid for research Program year 2021 Source: CMS Open Payments

SDMD Research

Neither a doctor nor a teaching hospital

Research payments

$363,182

50 payments

Through program year 2021, SDMD Research is reported as receiving $363,182 in research payments, across 50 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$6,705	3
2020	Research	$180,182	25
2019	Research	$176,295	22

Breakdown

Who paid Research payments · program years 2019–2021

Allergan Inc. $363,182 50 payments

Studies the money was for Research payments · program years 2019–2021

P2b BTX Platysma Study $127,867 12 payments
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition $71,892 16 payments
BOTOX (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 2b, Multicenter, Randomized, Double Blind, Multi-Dose, Placebo-Controlled Study $64,646 9 payments
BOTOX onabotulinumtoxinA Treatment of Masseter Muscle Prominence A Phase 2b, Multicenter, Randomized, Double Blind, Multi-Dose, Placebo-Controlled Study $50,094 7 payments
Impact of Botox treatment on mood and self-appearance satisfaction in non-naive post Covid-19 $22,838 1 payment
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVEDERM VOLUXA XC injectable gel for restoring jawline definition $9,744 1 payment
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of JUVEDERM VOLUX XC injectable gel for restoring jawline definition $9,396 1 payment
A multicenter, evaluator-blinded, randomized, parallel-group, controlled study of the safety and effectiveness of Juvederm VOLUMA XC injectable gel for restoring jawline definition $6,705 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.